How Long Until GLP-1s Work? Weight Loss Timeline Week by Week

You started the shot a few weeks ago and you keep asking the scale the same question: when is this supposed to work? Here is the part nobody explains clearly. You are actually waiting on two different clocks. Appetite suppression is the fast one — most people feel it within the first week. Weight loss is the slow one, because even a solid 500-calorie daily deficit only moves the scale about a pound a week. The trial numbers everyone quotes — 15% to 22% body weight — happened over 68 to 72 weeks, not 12.

Confusing those two timelines is the single most common reason people quit a GLP-1 while it is working exactly as designed. This guide walks the full arc week by week: when appetite drops, when the scale starts moving, when it accelerates, when it plateaus, why some people stall — and what the slow-responder data says about how long to actually give it before judging.

If you are still choosing a provider, we track weight-loss clinics in Houston, Miami, and Los Angeles with verified availability.

The two timelines that matter

Two processes run on different clocks. The first is appetite suppression — when the drug turns down hunger. The second is weight loss — when that turned-down hunger shows up on the scale. They are not the same, and treating them as one is why so many people conclude a GLP-1 "isn't working" during a stretch when it is doing precisely what the pharmacology predicts.

Appetite suppression is fast. Weight loss is slow, because a 500-calorie daily deficit produces roughly one pound a week. Quitting early forfeits the part that hasn't happened yet — and stopping has its own cost, covered in weight regain after stopping GLP-1s.

Weeks 1–2: when appetite suppression begins

GLP-1s suppress appetite through two mechanisms running at different speeds. The fast one is peripheral: receptors in your gut signal the vagus nerve that your stomach is fuller than it is, producing early satiety. This starts with the first dose and is usually noticeable within 3 to 7 days. The slower one is central — receptors in the brain dial down the pull of high-reward food independent of hunger. That "food just doesn't interest me" effect typically takes two to four weeks to establish and is often strongest at months three to six.

In the STEP-1 trial of semaglutide, appetite scores dropped significantly within the first two weeks; reduced appetite was among the earliest reported effects in SURMOUNT-1 with tirzepatide too. At starting doses (0.25 mg semaglutide, 2.5 mg tirzepatide) the effect is real but milder by design, to let your gut adapt. Just don't mistake early nausea for appetite suppression — one persists, one is temporary, and our GLP-1 side effects timeline separates the two.

Weeks 2–8: first measurable weight loss

Most people lose two to six pounds in the first month. The range comes down to starting dose, how much you actually change your eating, and your metabolic rate. Across the major Phase 3 trials, weight loss at eight weeks is around 2–4% of body weight — at a 250-pound start, that is roughly five to ten pounds. That is not dramatically beyond intensive dieting alone, because you are still in the titration phase, not the therapeutic dose.

This is exactly where expectations and reality diverge. The common pattern: lose four pounds the first month, decide it "isn't working," quit. In fact 2.5 mg tirzepatide is pharmacologically different from 10 mg — not just a smaller version of the same effect. The tirzepatide dosing guide shows how the dose-response curve steepens as you climb. The people who hit trial-level results use the appetite signal to actively eat smaller, protein-forward meals rather than eating to their old normal.

Months 2–6: the acceleration phase

As you approach maintenance dose, the rate of loss accelerates. STEP-1 showed a near-linear decline from months two through twelve at 2.4 mg semaglutide; SURMOUNT-1 showed its steepest drop between months two and eight at the higher tirzepatide doses. The drivers stack: higher dose, stronger appetite suppression, behavioral adaptation, and a compounding deficit. A one-pound week can become a two-pound week for people who stay compliant and eat to the signal.

For women in perimenopause, estrogen status shapes this phase — postmenopausal women on hormone therapy have shown improved response to semaglutide, which we cover in GLP-1 medications and HRT. Protein intake matters from week one, not month six: under-eating protein costs you muscle and, with it, metabolic rate — the same nutritional gap behind GLP-1 hair loss in many women.

Months 6–12: approaching maximum effect

STEP-1 (semaglutide) flattened toward a plateau around months twelve to sixteen. SURMOUNT-1 (tirzepatide) had a longer runway, beginning to plateau around months sixteen to twenty — and the 15 mg curve had not fully flattened by week 72. Practically, the year-one number is not the final number for most people, especially on tirzepatide; the curve keeps drifting down more slowly into year two.

By month six, someone headed for 20%+ should be down roughly 10–12%. If you are at month six and below 5%, three questions are worth asking your provider: are you actually at your target maintenance dose yet, are you eating meaningfully less than before, and is something else — thyroid, sleep apnea, certain medications — blunting the response?

Why am I not losing weight?

The most common reason for an early stall is simple: you are not at maintenance dose yet. People conflate "I've been on this six months" with "I've been at the therapeutic dose six months," and they are rarely the same — it takes at least 20 weeks to climb to the top tirzepatide dose. Other culprits: the body lowering its metabolic rate in response to the deficit, inadequate protein driving muscle loss, and poor sleep, which spikes hunger hormones upstream of the drug's signal.

Here is the data that should keep you from quitting too soon. A 2025 post-hoc analysis of SURMOUNT-1 found that among "late responders" to tirzepatide, the mean time to reach 5% weight loss was about 24.8 weeks — and 90% of them still reached at least 5% by week 72. In other words, a slow start is not a failed start. Twelve weeks is too early to call it; most clinicians look at response closer to 20+ weeks at an adequate dose before changing course.

The numbers at one year and beyond

Semaglutide 2.4 mg at 68 weeks: mean −14.9%, with a range of roughly −5% to −25%. Tirzepatide 15 mg at 72 weeks: mean −22.5%, range roughly −10% to −40%. These are trial averages under close monitoring and full adherence per the FDA prescribing labels. Real-world results run lower, almost entirely because real-world adherence runs lower — about half of patients stop within a year, often before completing titration.

In year two, weight tends to stabilize rather than keep dropping for those who stay on. Those who stop regain about two-thirds of the loss within a year. If you plateau and want a stronger option, the next-generation triple agonist retatrutide hit 28.3% in Phase 3 without a clear plateau, and there are now FDA-approved oral GLP-1 options for people who want to drop the needle. One non-scale note: rapid loss is what drives Ozempic face, and GLP-1s can restore fertility in women with PCOS — see GLP-1 medications and fertility if pregnancy is on the table. To find a prescriber, we list tirzepatide providers in San Antonio and semaglutide providers in Houston.

Frequently asked questions

How long does it take for semaglutide to suppress appetite?

Most people notice reduced appetite within the first 3 to 7 days of starting semaglutide, driven by the fast peripheral satiety effect. A second, central effect — where high-reward foods simply lose their pull — builds more gradually over two to four weeks and is often strongest at months three to six. At the 0.25 mg starting dose the effect is intentionally mild to let your gut adapt, and it strengthens as you titrate up. If you feel almost nothing in the first weeks, that is common at the starting dose and usually changes as the dose increases.

How fast does a GLP-1 start working for weight loss?

Appetite changes come within days, but visible weight loss is slower. Most people lose about two to six pounds in the first month and roughly 2–4% of body weight by week eight — still in the titration phase. The faster, larger losses come during months two to six as you reach your maintenance dose. Expecting dramatic scale movement in the first month is the most common reason people quit prematurely. A realistic frame: meaningful, steady loss builds over months, not weeks, and accelerates once you are at the therapeutic dose.

Why am I not losing weight on Ozempic?

The most common reason is that you have not reached the therapeutic maintenance dose yet — being "on Ozempic for months" is not the same as being at the effective dose for months. Other causes include the body lowering its metabolic rate in response to the deficit, inadequate protein leading to muscle loss, poor sleep raising hunger hormones, and conditions like hypothyroidism. A 2025 analysis also found many slow responders take around 25 weeks to hit 5% loss yet still get there — so a slow start is often just slow, not failed. Talk to your provider about dose and timeline before concluding it is not working.

How much weight will I lose in the first month?

Typically two to six pounds in the first month, depending on your starting dose, how much you change your eating, and your metabolism. That works out to around 2–4% of body weight by week eight in clinical trials — modest, because the first weeks are a low starting dose meant to build tolerance, not the full therapeutic dose. People who use the appetite suppression to genuinely cut portions lose toward the higher end. Do not extrapolate the first month across the year: the rate increases substantially once you reach maintenance dose in months two through six.

What is the Zepbound (tirzepatide) weight loss timeline?

Zepbound follows the same shape as other GLP-1s but with a longer runway. Appetite drops in the first week or two; measurable loss appears by weeks two to eight; the steepest decline runs roughly months two to eight as you climb the six-step dose schedule; and the curve begins to plateau around months sixteen to twenty. In SURMOUNT-1, mean loss reached 22.5% at 15 mg by week 72, and the highest-dose curve had not fully flattened — so results can keep building into year two. Reaching the top dose takes at least 20 weeks, which is why early months understate the eventual result.

How long should I stay on a GLP-1 before deciding it isn't working?

Give it at least 20 weeks at an adequate dose before judging — not the common 12-week checkpoint. The reason is dosing: it takes roughly five months to titrate to the top tirzepatide dose, so a "non-response" at week 12 often just means you have not reached the effective dose. A 2025 SURMOUNT-1 analysis found slow responders averaged about 25 weeks to reach 5% loss, and 90% of them got there by week 72. If you are at a stable maintenance dose, eating less, and still seeing nothing by around 20+ weeks, that is the point to reassess dose or evaluate other causes with your provider.